Biopharma AI
By
Can ProFound Therapeutics and Novartis’ $750M AI-Driven Cardiovascular Pact Redefine Drug Discovery from the Human Proteome?
Key Highlights AI Meets Proteomics: A New Paradigm in Cardiovascular DiscoveryIn a bold step toward AI-enabled medicine, ProFound…
Is Insilico’s AI-Driven UAE University Alliance the Catalyst for a New Generation of Biotech Talent?
Key Highlights Academic Meets AI Innovation in UAEInsilico Medicine, a leader in generative AI for drug discovery, has…
Is Sanofi’s $632M AI Bet on Formation Bio the Next Big Immunology Breakthrough?
French pharma giant doubles down on AI-native R&D with gusacitinib licensing deal targeting new inflammatory indication Key Takeaways…
Accelerating Drug Discovery with Artificial Intelligence: Strategic Insights from Pharma’s Biggest AI Alliances
Executive SummaryThe convergence of artificial intelligence (AI) and drug discovery is a strategic imperative. Pharmaceutical giants including Sanofi,…
Can Lisata Therapeutics and GATC Health’s AI Breakthrough Redefine Drug Discovery and Tackle the Opioid Crisis in Just One Year?
Key Highlights AI-Powered Drug Discovery Moves Toward the Clinic with OUD FocusLisata Therapeutics and GATC Health have expanded…
Is Merck’s $10B Acquisition of Verona a Strategic Masterstroke to Offset Keytruda’s Patent Cliff and Dominate the $30B+ Respiratory Market?
Key Highlights Merck Secures Verona to Bridge Its Post-Keytruda Future Merck & Co. has taken a bold step…
